Published • loading... • Updated
Weight loss drugs linked to increased risk of hair loss, researchers say
Researchers found GLP-1 drugs were linked to a 37% higher alopecia risk than SGLT-2 inhibitors and a 68% higher risk than DPP-4 inhibitors.
- On Wednesday, a study published in The BMJ linked GLP-1 drugs—including Wegovy, Ozempic, Mounjaro, and Zepbound—to a higher risk of alopecia in type 2 diabetes patients compared to SGLT-2 and DPP-4 inhibitors.
- Researchers at the University of Pennsylvania Health System reported a 37% higher risk of hair loss for GLP-1 users compared to SGLT-2 inhibitors, and a 68% higher risk versus DPP-4 inhibitors.
- While the risk remains low at roughly 7 people per 1,000 annually, the team cited "reduced caloric intake" as the "most likely mechanism" disrupting hair growth cycles.
- The US Food and Drug Administration is evaluating the safety signal, while the UK Medicines and Healthcare products Regulatory Agency has received 399 reports of hair loss linked to tirzepatide in 2026.
- Separate research suggests hair loss is often reversible, though experts advise patients to weigh this potential adverse effect against the "substantial and well-established benefits" of GLP-1 therapies for obesity and diabetes.
Insights by Ground AI
33 Articles
33 Articles
Alopecia is a possible side effect of LPG-1 receptor agonists
·Madrid, Spain
Read Full Article
Coverage Details
Total News Sources33
Leaning Left7Leaning Right6Center12Last UpdatedBias Distribution48% Center
Bias Distribution
- 48% of the sources are Center
48% Center
L 28%
C 48%
R 24%
Factuality
To view factuality data please Upgrade to Premium
